We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

ROCHE DIAGNOSTICS CORP

Roche Diagnostics Corporation is the North American headquarters of Roche Diagnostics, a global leader in diagnostics... read more Featured Products: More products

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Blood Test Predicts Immunotherapy Efficacy

By LabMedica International staff writers
Posted on 20 Sep 2017
Print article
Image: The Tumor Mutation Burden test detects cell free tumor DNA in the blood and allows for stratification of patients not eligible to have a tumor biopsy (Photo courtesy of the US National Cancer Institute).
Image: The Tumor Mutation Burden test detects cell free tumor DNA in the blood and allows for stratification of patients not eligible to have a tumor biopsy (Photo courtesy of the US National Cancer Institute).
A test developed with the US-based genetic testing specialist could be significant because, although potent, it is difficult to predict which patients will respond to immunotherapies, which are setting new care standards in some types of tumors.

This and the tough side-effects associated with immunotherapies have led to some unpleasant surprises where trials have produced unexpected failures, and but scientist hope that testing Tumor Mutation Burden (TMB) will more accurately predict where immunotherapies will succeed.

TMB is a clinical marker that measures the number of mutations within a tumor genome, and the new data show for the first time that a blood-based test can measure this with a high degree of precision and accuracy. TMB has been found to be an indicator of likelihood of progression-free survival (PFS) benefit from immunotherapies when used alone (monotherapy) in patients with non-small cell lung cancer (NSCLC).

Until now TMB could only be measured using an invasive tumor biopsy, and a blood test could extend tests to patients unable to undergo these procedures, or where tissue is unavailable or of insufficient size to evaluate. The blood TMB (bTMB) biomarker study was conducted using 794 plasma samples from the pivotal phase 2 POPLAR and phase 3 OAK Tecentriq studies. The purpose of the analysis was to collect initial, retrospective evidence of an association between bTMB and Tecentriq activity. These early data will inform ongoing and future prospective studies to better understand the role of both TMB and bTMB as it relates to treatment with cancer immunotherapy.

The blood test for TMB was developed by Roche (Basel, Switzerland) and Foundation Medicine (Cambridge, MA, USA) and has shown it can accurately measure the number of mutations within a tumor, potentially helping doctors predict which patients may respond best to some immunotherapies. Sandra Horning, MD, Roche's chief medical officer, said, “Biomarkers will not only improve our understanding of immune biology but will ultimately help match our therapies and combinations to the people most likely to benefit. This blood-based TMB assay is one example of how we and our partners are advancing the science towards personalization of cancer therapy.” The study was presented at the European Society of Medical Oncology Congress held September 8-12, 2017, in Madrid, Spain.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The medical office procedure detects the key biomarker in Parkinson’s and related neurodegenerative diseases (Photo courtesy of BIDMC)

Simple Skin Biopsy Test Detects Parkinson’s and Related Neurodegenerative Diseases

Parkinson's disease and a group of related neurodegenerative disorders known as synucleinopathies impact millions globally. These conditions, including Parkinson’s disease (PD), dementia with Lewy bodies... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.